CBC

CBC (cannabichromene) is the third most common cannabinoid in most cannabis chemovars after THC and CBD, though it remains relatively understudied compared to its more famous siblings. CBC was first identified in 1966 and is biosynthesized from CBGA (the parent cannabinoid) through the CBC synthase enzyme. CBC is non-psychoactive — it does not bind CB1 receptors significantly and produces no intoxication. Instead, CBC acts primarily through: TRPV1 vanilloid receptors (involved in pain and inflammation regulation), TRPA1 receptors (involved in pain perception), inhibition of anandamide uptake (extending the body's natural euphoric neurotransmitter), and CB2 receptors at moderate affinity (immune system modulation). Documented therapeutic potential: antidepressant effects (CBC shows mood-elevating activity in rodent forced-swim tests, suggesting potential as a mood disorder treatment), neurogenesis promotion (laboratory studies show CBC increases viability of developing brain cells, suggesting neuroprotective and Alzheimer's relevance), anti-inflammatory effects comparable to ibuprofen in animal models, antimicrobial activity (effective against various bacteria including MRSA), pain relief without psychoactivity, and antitumor activity against breast cancer cells in vitro. CBC contributes to the entourage effect — the synergistic interaction of multiple cannabinoids and terpenes producing effects beyond what any single compound creates alone. Most full-spectrum cannabis extracts contain 0.5-2% CBC, contributing to the broader therapeutic profile beyond just THC and CBD content. Selective CBC breeding is in early stages — a few breeders are working on high-CBC strains, but no commercial product has reached the market with the dominant CBC profile. CBC is widely available in full-spectrum hemp extracts and in some emerging single-cannabinoid CBC isolate products.